Susanne Alban

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8135368/publications.pdf

Version: 2024-02-01

68 papers	2,334 citations	185998 28 h-index	214527 47 g-index
75 all docs	75 docs citations	75 times ranked	2323 citing authors

#	Article	IF	Citations
1	The COVIDâ€•19 vaccine ChAdOx1â€S is not contaminated with sulfated glycosaminoglycans. Journal of Thrombosis and Haemostasis, 2022, 20, 777-780.	1.9	5
2	Sulfated Polysaccharides from Macroalgae Are Potent Dual Inhibitors of Human ATP-Hydrolyzing Ectonucleotidases NPP1 and CD39. Marine Drugs, 2021, 19, 51.	2.2	8
3	Influence of Fucoidan Extracts from Different Fucus Species on Adult Stem Cells and Molecular Mediators in In Vitro Models for Bone Formation and Vascularization. Marine Drugs, 2021, 19, 194.	2.2	15
4	Evaluation of the Effects of Fucoidans from Fucus Species and Laminaria hyperborea against Oxidative Stress and Iron-Dependent Cell Death. Marine Drugs, 2021, 19, 557.	2.2	16
5	Degraded fucoidan fractions and Î²-1,3-glucan sulfates inhibit CXCL12-induced Erk1/2 activation and chemotaxis in Burkitt lymphoma cells. International Journal of Biological Macromolecules, 2020, 143, 968-976.	3.6	5
6	Initial evaluation of six different brown algae species as source for crude bioactive fucoidans. Algal Research, 2020, 45, 101759.	2.4	42
7	Size distribution and chain conformation of six different fucoidans using size-exclusion chromatography with multiple detection. Journal of Chromatography A, 2020, 1612, 460658.	1.8	25
8	Evaluation of a Brown Seaweed Extract from Dictyosiphon foeniculaceus as a Potential Therapeutic Agent for the Treatment of Glioblastoma and Uveal Melanoma. Marine Drugs, 2020, 18, 625.	2.2	4
9	Comparison of the Effects of Fucoidans on the Cell Viability of Tumor and Non-Tumor Cell Lines. Marine Drugs, 2019, 17, 441.	2.2	28
10	Effects of Crude Fucus distichus Subspecies evanescens Fucoidan Extract on Retinal Pigment Epithelium Cellsâ€•Implications for Use in Age-Related Macular Degeneration. Marine Drugs, 2019, 17, 538.	2.2	18
11	Effects of Fucoidans from Five Different Brown Algae on Oxidative Stress and VEGF Interference in Ocular Cells. Marine Drugs, 2019, 17, 258.	2.2	35
12	Degradation of Eight Sulfated Polysaccharides Extracted from Red and Brown Algae and Its Impact on Structure and Pharmacological Activities. ACS Biomaterials Science and Engineering, 2019, 5, 1200-1214.	2.6	13
13	Size and molecular weight determination of polysaccharides by means of nano electrospray gasâ€phase electrophoretic mobility molecular analysis (nES GEMMA). Electrophoresis, 2018, 39, 1142-1150.	1.3	12
14	Size-dependent pharmacological activities of differently degraded fucoidan fractions from Fucus vesiculosus. Carbohydrate Polymers, 2018, 189, 162-168.	5.1	47
15	Gradual degradation of fucoidan from Fucus vesiculosus and its effect on structure, antioxidant and antiproliferative activities. Carbohydrate Polymers, 2018, 192, 208-216.	5.1	66
16	Effects of fucoidans and heparin on reactions of neutrophils induced by IL-8 and C5a. Carbohydrate Polymers, 2017, 165, 462-469.	5.1	10
17	Direct oral anticoagulants and heparins: laboratory values and pitfalls in â€˜bridging therapyâ€™. European Journal of Cardio-thoracic Surgery, 2017, 51, ezw368.	0.6	7
18	Regulation of Complement and Contact System Activation via C1 Inhibitor Potentiation and Factor XIIa Activity Modulation by Sulfated Glycans â€" Structure-Activity Relationships. PLoS ONE, 2016, 11, e0165493.	1.1	26

#	Article	IF	Citations
19	Sulfated Galactofucan from the Brown Alga Saccharina latissimaâ€”Variability of Yield, Structural Composition and Bioactivity. Marine Drugs, 2015, 13, 76-101.	2.2	53
20	Interference with the CXCL12/CXCR4 axis as potential antitumor strategy: superiority of a sulfated galactofucan from the brown alga<i>Saccharina latissima</i>and Fucoidan over heparins. Glycobiology, 2015, 25, 812-824.	1.3	43
21	Simple and Rapid Quality Control of Sulfated Glycans by a Fluorescence Sensor Assayâ€”Exemplarily Developed for the Sulfated Polysaccharides from Red Algae Delesseria sanguinea. Marine Drugs, 2014, 12, 2205-2227.	2.2	12
22	Dabigatran, rivaroxaban, apixaban, argatroban and fondaparinux and their effects on coagulation POC and platelet function tests. Clinical Chemistry and Laboratory Medicine, 2014, 52, 835-44.	1.4	101
23	Testing of potential glycan-based heparanase inhibitors in a fluorescence activity assay using either bacterial heparinase II or human heparanase. Journal of Pharmaceutical and Biomedical Analysis, 2014, 95, 130-138.	1.4	8
24	Adverse Effects of Heparin. Handbook of Experimental Pharmacology, 2012, , 211-263.	0.9	69
25	Development of both colorimetric and fluorescence heparinase activity assays using fondaparinux as substrate. Analytical Biochemistry, 2012, 427, 82-90.	1.1	8
26	Simple fluorescence assay for quantification of OSCS in heparin. Analytical and Bioanalytical Chemistry, 2011, 399, 673-680.	1.9	20
27	Comparison of established and novel purity tests for the quality control of heparin by means of a set of 177 heparin samples. Analytical and Bioanalytical Chemistry, 2011, 399, 605-620.	1.9	37
28	Combination of a two-step fluorescence assay and a two-step anti-Factor Xa assay for detection of heparin falsifications and protein in heparins. Analytical and Bioanalytical Chemistry, 2011, 399, 681-690.	1.9	15
29	Composition of OSCS-contaminated heparin occurring in 2008 in batches on the German market. European Journal of Pharmaceutical Sciences, 2010, 40, 297-304.	1.9	47
30	Development and evaluation of a fluorescence microplate assay for quantification of heparins and other sulfated carbohydrates. Journal of Pharmaceutical and Biomedical Analysis, 2010, 52, 1-8.	1.4	20
31	Editorial: Pharmazie in unserer Zeit 4/2009. Pharmazie in Unserer Zeit, 2009, 38, 295-295.	0.0	0
32	PS3, A Semisynthetic Î²-1,3-Glucan Sulfate, Diminishes Contact Hypersensitivity Responses Through Inhibition of L- and P-Selectin Functions. Journal of Investigative Dermatology, 2009, 129, 1192-1202.	0.3	29
33	Optimized and Standardized Isolation and Structural Characterization of Anti-inflammatory Sulfated Polysaccharides from the Red Alga Delesseria sanguinea (Hudson) Lamouroux (Ceramiales,) Tj ETQq1 1 0.784314 rg BT /Overlock 10 Tf	2.5	26
34	Evaluation of Seasonal Variations of the Structure and Anti-inflammatory Activity of Sulfated Polysaccharides Extracted from the Red Alga Delesseria sanguinea (Hudson) Lamouroux (Ceramiales,) Tj ETQq0 0 0 rg BT /Overlock 10 Tf	2.6	27
35	Pharmacological profiles of animal- and nonanimal-derived sulfated polysaccharides - comparison of unfractionated heparin, the semisynthetic glucan sulfate PS3, and the sulfated polysaccharide fraction isolated from Delesseria sanguinea. Glycobiology, 2008, 19, 408-417.	1.3	42
36	Elastase Inhibition Assay with Peptide Substrates â€“ An Example for the Limited Comparability of<i>in vitro</i>Results. Planta Medica, 2008, 74, 852-858.	0.7	17

#	Article	IF	Citations
37	Prothrombin Time for Detection of Contaminated Heparins. New England Journal of Medicine, 2008, 359, 2732-2734.	13.9	16
38	Pharmacological Strategies for Inhibition of Thrombin Activity. Current Pharmaceutical Design, 2008, 14, 1152-1175.	0.9	63
39	Affinity and Kinetics of Different Heparins Binding to P- and L-Selectin. Seminars in Thrombosis and Hemostasis, 2007, 33, 534-539.	1.5	25
40	Kinetic Analysis of Heparin and Glucan Sulfates Binding to P-Selectin and Its Impact on the General Understanding of Selectin Inhibition. Biochemistry, 2007, 46, 6156-6164.	1.2	28
41	Perioperative bridging with fondaparinux in a woman with antithrombin deficiency. Thrombosis and Haemostasis, 2007, 97, 498-499.	1.8	13
42	Role of Sulfated Polysaccharides in the Pathogenesis?of Heparin-Induced Thrombocytopenia. Fundamental and Clinical Cardiology, 2007, , 167-186.	0.0	4
43	The ability of different forms of heparins to suppress P-selectin function in vitro correlates to their inhibitory capacity on bloodborne metastasis in vivo. Thrombosis and Haemostasis, 2006, 95, 535-540.	1.8	98
44	Editorial: Pharmazie in unserer Zeit 1/2006. Pharmazie in Unserer Zeit, 2006, 35, 3-3.	0.0	0
45	The influence of various structural parameters of semisynthetic sulfated polysaccharides on the P-selectin inhibitory capacity. Biochemical Pharmacology, 2006, 72, 474-485.	2.0	51
46	Complement Modulating and Anticoagulant Effects of a Sulfated Exopolysaccharide Released by the Cyanobacterium Synechocystis aquatilis. Planta Medica, 2006, 72, 1424-1427.	0.7	4
47	Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities. Mini-Reviews in Medicinal Chemistry, 2006, 6, 1009-1023.	1.1	28
48	The 37â€kDa/67â€kDa Laminin Receptor Acts as a Receptor for Infectious Prions and Is Inhibited by Polysulfated Glycanes. Journal of Infectious Diseases, 2006, 194, 702-709.	1.9	115
49	From heparins to factor Xa inhibitors and beyond. European Journal of Clinical Investigation, 2005, 35, 12-20.	1.7	62
50	The 'precautionary principle' as a guide for future drug development. European Journal of Clinical Investigation, 2005, 35, 33-44.	1.7	25
51	Molecular weight determines the frequency of delayed type hypersensitivity reactions to heparin and synthetic oligosaccharides. Thrombosis and Haemostasis, 2005, 94, 1265-1269.	1.8	53
52	Î²-1,3 Glucan Sulfate, but Not Î²-1,3 Glucan, Induces the Salicylic Acid Signaling Pathway in Tobacco and Arabidopsis. Plant Cell, 2004, 16, 3020-3032.	3.1	172
53	Editorial: Pharmazie in unserer Zeit 3/2004. Pharmazie in Unserer Zeit, 2004, 33, 157-157.	0.0	0
54	Dendritic Polyglycerol Sulfates as New Heparin Analogues and Potent Inhibitors of the Complement System. Bioconjugate Chemistry, 2004, 15, 162-167.	1.8	127

#	Article	IF	Citations
55	Inhibition of PMN-elastase activity by semisynthetic glucan sulfates. Thrombosis and Haemostasis, 2003, 89, 915-25.	1.8	6
56	Differentiation Between the Complement Modulating Effects of an Arabinogalactan-Protein fromEchinacea purpureaand Heparin. Planta Medica, 2002, 68, 1118-1124.	0.7	51
57	Pharmacokinetic and Pharmacodynamic Characterization of a Medium-Molecular-Weight Heparin in Comparison with UFH and LMWH. Seminars in Thrombosis and Hemostasis, 2002, 28, 369-378.	1.5	14
58	Partial Synthetic Glucan Sulfates as Potential New Antithrombotics:Â A Review. Biomacromolecules, 2001, 2, 354-361.	2.6	58
59	Plasma Levels of Total and Free Tissue Factor Pathway Inhibitor (TFPI) as Individual Pharmacological Parameters of Various Heparins. Thrombosis and Haemostasis, 2001, 85, 824-829.	1.8	42
60	Development of SPC-ELISA: A New Assay Principle for the Study of Sulfated Polysaccharide-Protein Interactions. Journal of Biomolecular Screening, 2001, 6, 393-400.	2.6	8
61	Molecular Weight-Dependent Influence of Heparin on the Form of Tissue Factor Pathway Inhibitor Circulating in Plasma. Seminars in Thrombosis and Hemostasis, 2001, 27, 503-512.	1.5	27
62	Development of SPC-ELISA: A New Assay Principle for the Study of Sulfated Polysaccharideâ€“Protein Interactions. Journal of Biomolecular Screening, 2001, 6, 393-400.	2.6	1
63	Characterization of the Anticoagulant Actions of a Semisynthetic Curdlan Sulfate. Thrombosis Research, 2000, 99, 377-388.	0.8	55
64	Biological Activities and Effects on the Platelet Aggregation of a Structurally Defined Curdlan Sulfate. , 1996, , 235-242.		1
65	Novel pharmaceutical applications of polysaccharides. Macromolecular Symposia, 1995, 99, 187-200.	0.4	8
66	Anticoagulant and antithrombotic actions of a semisynthetic Î²-1,3-glucan sulfate. Thrombosis Research, 1995, 78, 201-210.	0.8	43
67	Characterization of the Structural Requirements for a Carbohydrate Based Anticoagulant with a Reduced Risk of Inducing the Immunological Type of Heparin-associated Thrombocytopenia. Thrombosis and Haemostasis, 1995, 74, 886-892.	1.8	139
68	Gas-Liquid Chromatography-Mass Spectrometry Analysis of Anticoagulant Active Curdlan Sulfates. Seminars in Thrombosis and Hemostasis, 1994, 20, 152-158.	1.5	37